Immunic Fundamentals

IMUX -  USA Stock  

USD 8.68  0.04  0.46%

Immunic fundamentals help investors to digest information that contributes to Immunic's financial success or failures. It also enables traders to predict the movement of Immunic Stock. This fundamental analysis module provides a way for investors to measures Immunic's intrinsic value by examining all of its available economic and financial indicators and drivers, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immunic stock. Please note, this module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Immunic Fundamentals 

 
Refresh
Immunic Selling General and Administrative Expense is fairly stable at the moment as compared to the past year. Immunic reported Selling General and Administrative Expense of 10.33 Million in 2020. Weighted Average Shares is likely to rise to about 16.9 M in 2021, whereas Consolidated Income is likely to drop (47.5 M) in 2021.

Immunic Shares Owned by Institutions Analysis

Immunic's Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
 2018 2019 2020 2021 (projected)
Current Assets13.33 M32.23 M133.75 M105.89 M
Total Assets13.37 M65.95 M167.86 M181.11 M
Shares Held by Institutions 
 = 
Funds and Banks 
Firms 
More About Shares Owned by Institutions | All Equity Analysis

Current Immunic Shares Owned by Institutions

    
  37.51 %  
Most of Immunic's fundamental indicators, such as Shares Owned by Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunic is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Compare to competition

Based on the latest financial disclosure, 37.51% of Immunic are shares owned by institutions. This is 15.97% lower than that of the Healthcare sector and 21.03% lower than that of the Biotechnology industry. The shares owned by institutions for all United States stocks is 4.34% higher than that of the company.

Immunic Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Immunic's current stock value. Our valuation model uses many indicators to compare Immunic value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immunic competition to find correlations between indicators driving Immunic's intrinsic value. More Info.
Immunic is considered the number one company in current valuation category among related companies. It is considered the number one company in total debt category among related companies making up about  0.01  of Total Debt per Current Valuation. The ratio of Current Valuation to Total Debt for Immunic is roughly  157.95 . Immunic Total Debt is fairly stable at the moment as compared to the past year. Immunic reported Total Debt of 679,000 in 2020. Comparative valuation analysis is a catch-all model that can be used if you cannot value Immunic by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Immunic's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immunic's earnings, one of the primary drivers of an investment's value.

Immunic Current Ratio Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunic's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunic could also be used in its relative valuation, which is a method of valuing Immunic by comparing valuation metrics of similar companies.
Immunic is currently under evaluation in current ratio category among related companies.

Immunic Current Valuation Drivers

We derive many important indicators used in calculating different scores of Immunic from analyzing Immunic's financial statements. These drivers represent accounts that assess Immunic's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Immunic's important valuation drivers and their relationship over time.
201620172018201920202021 (projected)
Average Assets74.51 M75.59 M28.79 M54.15 M120.99 M103.97 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(39.16 M)(51.08 M)(11.53 M)(34.88 M)(43.98 M)(47.45 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(39.16 M)(51.08 M)(11.53 M)(34.88 M)(43.98 M)(47.45 M)
Earnings before Tax(40.97 M)(52.08 M)(11.54 M)(34.93 M)(44.02 M)(47.49 M)
Average Equity69.6 M67.47 M13.06 M49.34 M112.71 M89.07 M
Enterprise Value71.32 M184.74 M(9.9 M)67.68 M184.34 M175.32 M
Free Cash Flow(36.33 M)(41.08 M)(9.77 M)(28.56 M)(46.27 M)(49.92 M)
Invested Capital(1.45 M)(6.8 M)(1.62 M)(2.94 M)(279 K)(301.03 K)
Invested Capital Average(369.25 K)(3.99 M)(4.01 M)(1.5 M)(877.75 K)(947.05 K)
Market Capitalization139.42 M251.13 M7.89 M98.14 M316.78 M272.49 M
Tangible Asset Value64.03 M60.38 M13.37 M32.98 M134.89 M107.65 M
Working Capital55.98 M47.84 M11.41 M25.16 M125.35 M135.24 M

Immunic Fundamentals

About Immunic Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Immunic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. t and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 45 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Immunic without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Fundamental Analysis Now

   

Fundamental Analysis

View fundamental data based on most recent published financial statements
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immunic using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Immunic Piotroski F Score and Immunic Altman Z Score analysis. Note that the Immunic information on this page should be used as a complementary analysis to other Immunic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try CEO Directory module to screen CEOs from public companies around the world.

Complementary Tools for Immunic Stock analysis

When running Immunic price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Is Immunic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunic. If investors know Immunic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine Immunic value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.